STIMEL-03: Accelerating Recovery with Tailored Stimulation
An FDA-cleared, EMG-driven neuromuscular stimulation system integrating Functional Electrical Stimulation (FES), Neuromuscular Electrical Stimulation (NMES), and real-time biofeedback into a single adaptive rehabilitation solution. Powered by BioRhythmIQ technology, Stimel-03 captures electromyographic signals, analyzes neuromotor intent in real time, and delivers precisely timed stimulation to reinforce correct motor activation patterns.
-
Accelerated Motor Recovery
EMG-triggered stimulation reinforces voluntary intent in real time, driving faster functional gains and measurable improvement in activities of daily living.
-
Active Neuroplasticity Engagement
Synchronization of brain intent, visual biofeedback, and electrical stimulation strengthens motor pathways and supports durable neural rewiring.
-
Personalized Patient-Specific Therapy
Individual EMG thresholds and adaptive stimulation parameters reduce fatigue, prevent over-stimulation, and align therapy with each patient's neuromuscular status.
-
Early & Chronic Stage Applicability
High-sensitivity EMG detection enables intervention even when visible movement is minimal, supporting early post-stroke care and long-term rehabilitation.
Why Stimel-03
Key Differentiators
-
BioRhythmIQ-Guided Therapy
EMG-guided, intent-triggered stimulation fires only when the patient's voluntary signal reaches the calibrated threshold — reinforcing correct motor recruitment.
-
Real-Time Timing Alignment
Stimulation is synchronized with neuromotor intent, not delivered on a fixed schedule — converting passive stimulation into active neuromuscular re-education.
-
Measurable Progress Tracking
Session data is tracked longitudinally, enabling clinicians to quantify improvement and adapt protocols with objective evidence.
-
Early Intervention Capability
High-sensitivity EMG detection captures ultra-low voluntary signals, enabling intervention even when visible movement is absent.
-
Clinically Differentiated Revenue
FDA-cleared, patent-based biofeedback technology combined with recurring electrode consumption supports sustainable clinical deployment and distributor scalability.
-
Improved Engagement & Adherence
Real-time visual feedback transforms therapy into an interactive process, increasing patient motivation, compliance, and session effectiveness.
Precision Technology
Adaptive Biofeedback
BioRhythmIQ technology captures patient-specific electromyographic signals and displays them in real time. The dynamic EMG threshold algorithm recalibrates continuously based on performance and fatigue — once the patient’s muscle activation reaches a dynamically calibrated threshold, stimulation fires to reinforce correct motor execution. Passive stimulation becomes active neuromuscular re-education.
- Real-time surface EMG detection of voluntary motor intent
- Intent-triggered stimulation synchronized with patient effort
- Patient-specific threshold calibration and adaptive delivery to reduce fatigue
Autonomous Recovery
Closed-Loop Precision
Stimel-03 delivers measurable clinical outcomes: ADL improvement (FIM) of +50.6% vs +20.7% in controls; hand function (Fugl-Meyer) +67.4% vs +34.8%; stroke severity (NIHSS) -48.7% vs -26.2%. Recovery is 2.3x faster than controls, with fewer sessions. The system detects ultra-low EMG signals, enabling early intervention even when visible movement is minimal.
- Patient improvement rate in clinical trials
- 93%
- Sensor-to-stimulation response latency
- <5ms
- Faster recovery vs. conventional FES
- 2.1×
Technical Specifications
Standard performance metrics for clinical evaluation.
| Parameter | Value | Notes |
|---|---|---|
| Pulse Width | 50-1000 µs | Adjustable in 10µs increments |
| Current Amplitude | 0-120 mA | Constant current source |
| Frequency Range | 1-150 Hz | Supports burst mode patterns |
| Power Source | Li-Ion Rechargeable | Up to 12 hours clinical usage |
| EMG Sensing | Surface EMG (sEMG) | Single electrode setup for both sensing and stimulation |
| Operational Modes | Automatic / Manual / Biofeedback | Switchable per session protocol |
| Regulatory Status | FDA 510(k) Cleared - K 130424 | Class II Medical Device · 21 CFR 890.5850 |
| Patent | US Patent 7,221,980 B2 | BioRhythmIQ Technology |
| Intended Settings | Hospitals, Rehabilitation Centers, Neurology, OT/PT Clinics, Home Use | Home use under clinical guidance |
Product Demonstration
See STIMEL-03® in Action
Watch real clinical demonstrations of the STIMEL-03® neuromuscular stimulation system delivering precise, intent-triggered therapy.
Ready to transform patient recovery?
Join hundreds of clinical centers worldwide already utilizing the STIMEL-03 system.